Galux

, founded in 2020, is headquartered in Seoul, South Korea, and focuses on the innovative field of drug discovery. In February 2026, Galux Inc. Galux specializes in in silico drug discovery, leveraging an integrated technology platform that combines principles from physics, chemistry, and artificial intelligence to enhance the drug development process. The cornerstone of Galux's offerings is the GALAXY protein structure modeling platform, recognized as one of the leading methods globally, validated through comparative studies like CASP and CAPRI. By enabling precise modeling of protein structures, Galux's solutions aim to address critical challenges in drug design, including target identification and optimization of lead compounds. The company's client base primarily includes pharmaceutical and biotechnology companies that seek to expedite their drug discovery pipeline, with a focus on markets such as North America, Europe, and Asia. Galux generates revenue through various business models tailored to the needs of its clients. The primary structure comprises partnerships and subscription-based access to its GALAXY modeling platform, allowing clients to utilize advanced computational tools for drug discovery. Clients engage with Galux on a contractual basis, where they can access specific services or software licensing for a set period, facilitating ongoing support and updates. Transaction models are designed to accommodate both small biotech firms and larger pharmaceutical companies, ensuring scalability in their offerings. While specific pricing details remain undisclosed, the revenue streams are expected to be aligned with the high value placed on innovative solutions in the competitive pharmaceutical landscape.

1. Series B

   Feb 9, 2026

   Amount

   $29M

   Investors

   Locked

2. Series A

   Jul 12, 2022

   Amount

   $3.1M

   Investors

   Locked